PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis

August 28, 2017

PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class of cholesterol lowering treatments, may also reduce thrombosis by interfering with platelet activation.

Proprotein convertase subtilisin/kexin 9 (PCSK9) is a main player in cholesterol homeostasis by inducing degradation of the low density lipoprotein (LDL) cholesterol receptor. Emerging evidence indicates that plasma levels of PCSK9 predict recurrent cardiovascular events, for example myocardial infarction and angina, in patients with coronary artery disease, even in those with well controlled LDL cholesterol levels.

"We hypothesised that the contribution of PCSK9 to cardiovascular events might be mediated by as yet unknown cholesterol-independent pathways," said last author Dr Marina Camera, associate professor of pharmacology, University of Milan, Italy. "It has been reported that increased plasma levels of PCSK9 are associated with reactivity. However, no study has so far evaluated whether or not PCSK9 directly affects the function of platelets."

Platelets play a key role in the acute, thrombotic complications of atherosclerosis by causing life-threatening ischaemic events at a late stage of the disease. Increased platelet activation (called platelet hyperreactivity) has been reported in patients with and type 2 .

This study evaluated whether PCSK9 modulates platelet activation. It also assessed whether PCSK9 is expressed in platelets from healthy subjects, stable angina patients, and patients with type 2 diabetes mellitus.

The effect of PCSK9 on was studied using epinephrine-induced platelet aggregation in platelet-rich plasma preincubated or not with PCSK9. The effect of PCSK9 on platelet activation was investigated with whole blood flow cytometry evaluation of P-selectin, PAC-1 and tissue factor expression induced by epinephrine. PCSK9 expression in platelets was assessed by flow cytometry and further evaluated by western blot analysis in platelets and human megakaryocytes. PCSK9 levels were measured in platelets from 30 patients with stable angina (15 with diabetes, 15 without), ten patients with diabetes but without stable angina, and ten healthy people.

The investigators showed for the first time that:

  • PCSK9 is expressed in human megakaryocytes, the cells in the bone marrow responsible for producing circulating platelets. A subset of circulating platelets contains PCSK9, suggesting that there is a finely tuned mechanism for the direct transfer of PCSK9 from megakaryocytes to a certain number of platelets.
  • PCSK9 plays a role in platelet activation and aggregation.
  • Platelets from patients with both type 2 diabetes mellitus and stable angina contain twice the amount of PCSK9 as patients with only one, or neither, condition.

Dr Camera said: "Our data provide novel knowledge on the mechanisms regulating platelet activation in physiological and pathological conditions. Considering the contribution of platelets to cardiovascular disease, the findings also shed light on a new mechanism that may be involved in platelet hyperreactivity in patients with stable angina and diabetes mellitus."

She continued: "Based on our data it is possible that the pharmacological inhibition of PCSK9, besides down-regulating cholesterol levels, may have the added value of controlling the prothrombotic burden interfering with platelet activation."

Explore further: PCSK9 increased in females, youth with type 1 diabetes

Related Stories

PCSK9 increased in females, youth with type 1 diabetes

June 20, 2017
(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) is increased in young females and youth with type 1 diabetes (T1D), according to research published online June 6 in Diabetes Care.

Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective

August 22, 2017
An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater ...

New lipid-lowering drugs help patients reduce LDL cholesterol

August 1, 2016
A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.

PCSK9 monoclonal antibodies show promise in ACS

March 23, 2016
(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

Risk of cardiovascular disease and diabetes affected by PCSK9 and HMGCR genetic variations

November 30, 2016
In a new study published in the December 1, 2016 issue of The New England Journal of Medicine (NEJM), researchers at Brigham and Women's Hospital, and a collaboration of international researchers, studied variants in the ...

PCSK9 inhibitors reduce lipoprotein (a) production

October 31, 2016
A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, ...

Recommended for you

Laser device placed on the heart identifies insufficient oxygenation better than other measures

September 20, 2017
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital ...

Metabolism switch signals end for healing hearts

September 19, 2017
Researchers have identified the process that shuts down the human heart's ability to heal itself, and are now searching for a drug to reverse it.

Beta blockers not needed after heart attack if other medications taken

September 18, 2017
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge ...

Which single behavior best prevents high blood pressure?

September 15, 2017
(HealthDay)—You probably already know that certain healthy lifestyle behaviors can reduce your risk of developing high blood pressure, but is any one behavior more important than the others?

RESPECT trial shows closing a small hole in heart may protect against recurrent stroke

September 13, 2017
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial ...

Study shows so-called 'healthy obesity' is harmful to cardiovascular health

September 11, 2017
Clinicians are being warned not to ignore the increased cardiovascular health risks of those who are classed as either 'healthy obese' or deemed to be 'normal weight' but have metabolic abnormalities such as diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.